ArticleFrontiers in endocrinology2026
Prevalence and clinical relevance of negative histology after transsphenoidal surgery for pituitary neuroendocrine tumors.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Negative histology (NH), defined as normal pituitary tissue without histopathological evidence of tumor despite clinical, biochemical and radiological or functional evidence of a pituitary neuroendocrine tumor (PitNET), is well described in Cushing's disease but poorly characterized in other subtypes. We assessed its prevalence, mechanisms, and clinical implications. Methods: We retrospectively analyzed 651 patients who underwent transsphenoidal surgery for a PitNET (1996-2023). Epidemiological analyses included the entire cohort; clinical and prognostic analyses were restricted to microadenomas of the three main functional subtypes (ACTH, PRL, GH). Results: NH occurred in 28.1% of ACTH-, 28.1% of PRL-, and 11.4% of GH-secreting tumors, and was strongly associated with microadenomas. Baseline and hormonal characteristics were similar between NH and PH cases, except for lower IGF-1 levels in GH NH tumors. At 6 weeks, remission rates were lower in NH for ACTH (60% vs. 93.2%, Conclusion: NH is heterogeneous, arising from three mechanisms whose contributions vary by subtype. In ACTH tumors, mislocalization predominates and is associated with lower early remission. In PRL tumors, mislocalization is uncommon but may contribute to lower early remission. In GH tumors, NH likely reflects technical or histological limitations and carries a favorable prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.